Results 31 to 40 of about 11,284,409 (311)
Neurobiology of Disease, 2010 Benefit and motor side effects of l-DOPA in Parkinson's disease have been related to dopamine transmission in the striatum. However, the putative involvement of serotonergic neurons in the dopaminergic effects of l-DOPA suggests that the striatum is not ...
Sylvia Navailles +3 more
doaj +1 more source
Altered resting state cortico-striatal connectivity in mild to moderate stage Parkinson’s disease
Frontiers in Systems Neuroscience, 2010 Parkinson’s disease (PD) is a progressive neurodegenerative disorder that is characterized by dopamine depletion in the striatum. One consistent pathophysiological hallmark of PD is an increase in spontaneous oscillatory activity in the basal ganglia ...
Youngbin Kwak +9 more
doaj +1 more source
Striatal proteomic analysis suggests that first L-dopa dose equates to chronic exposure. [PDF]
PLoS ONE, 2008 L-3,4-dihydroxypheylalanine (L-dopa)-induced dyskinesia represent a debilitating complication of therapy for Parkinson's disease (PD) that result from a progressive sensitization through repeated L-dopa exposures. The MPTP macaque model was used to study
Birger Scholz +11 more
doaj +1 more source
Molecules, 2021 3,4-dihydroxyphenyl-L-alanine (L-DOPA) is a preferred drug for Parkinson’s disease, with an increasing demand worldwide that mainly relies on costly and environmentally problematic chemical synthesis.
Jiping Zhao +4 more
doaj +1 more source
Synthesis of L-DOPA based pigments with different physic-chemical properties [PDF]
, 2018 Using air- or Fe2+/H2O2-mediated oxidation, the formation of melanin-like pigments from L-DOPA was evaluated. The effects of the various reaction conditions on the efficiency of the reaction and the physic-chemical properties of the pigments generated ...
Koen, Vercruysse, Koen Vercruysse
core +1 more source
Journal of Parkinson’s Disease, 2017 Today we would find it difficult to place ourselves in the position of the physician or the patient prior to the L-DOPA era of Parkinson’s Disease (PD). David Marsden, the eminent British neurologist, neuroscientist and PD researcher of the second half of the last century and an eyewitness to that historical turning point, paints with few brush strokes,
openaire +3 more sources
, 2019 Introduction: Parkinson’s disease (PD), is a disorder debilitant characterized by the reduction of nigrostriatal dopaminergic neurons within the midbrain, specifically in the substantia nigra pars compacta, which results for the dopamine (DA) depletion ...
Lorenna Emília Sena Lopes (7860332) +3 more
core +1 more source
Dopamine transporter binding is unaffected by L-DOPA administration in normal and MPTP-treated monkeys. [PDF]
PLoS ONE, 2010 BackgroundRadiotracer imaging of the presynaptic nigrostriatal dopaminergic system is used to assess disease progression in Parkinson's disease (PD) and may provide a useful adjunct to clinical assessment during therapeutic trials of potential ...
Pierre-Olivier Fernagut +8 more
doaj +1 more source
Dopa-responsive dystonia and hyperprolactinaemia : a novel association in two sisters [PDF]
, 2007 Dopa-Responsive Dystonia (DRD) is a rare hereditary condition of childhood-onset dystonia which responds dramatically to treatment with levodopa. It was first described in 1971 as a "hereditary progressive basal ganglia disease with marked diurnal ...
Cachia, Mario J., Galea, Janabel
core
, 2017 Purpose: To develop elite genotypes in Mucuna pruriens (L.) DC with high L-DOPA (L-3, 4 dihydroxyphenylalanine) yields, with non-itching characteristics and better adaptability by applying γ-irradiation.
Deepti Yadav (3365363) +4 more
core +1 more source